Masimo Corporation (MASI) 52.33 $MASI Masimo Up 33.0%

New Post Public Reply Private Reply Replies (0) Message Board

Jul 10, 2016 at 7:19 PM

Masimo Corporation (MASI) 52.33 $MASI

Masimo Up 33.0% Since SmarTrend Uptrend Call (MASI)
Comtex SmarTrend(R) - Fri Jul 08, 12:46AM CDT
SmarTrend identified an Uptrend for Masimo (NASDAQ:MASI) on February 26th, 2016 at $39.09. In approximately 4 months, Masimo has returned 33.00% as of today's recent price of $51.99.
MASI: 52.33 (+0.34)

TrovaGene Inks Partnership with University of Michigan
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 3:31PM CDT
TrovaGene Inc. (TROV) is collaborating with the University of Michigan to conduct a multi-phased research program using Trovera KRAS ctDNA liquid biopsy test.
ABMD: 114.15 (+0.62), MASI: 52.33 (+0.34), TROV: 5.11 (+0.30), MLAB: 125.80 (+2.68)

One of the World's Leading Centers for Cardiovascular Medicine & Transplantation Adopts Masimo's SedLine(R) Brain Function Monitoring and O3(TM) Regional Oximetry
BusinessWire - Thu Jul 07, 7:03AM CDT
Masimo (NASDAQ: MASI) announced today that Deutsches Herzzentrum Berlin (DHZB / German Heart Center Berlin) in Berlin, Germany, has adopted Masimo's SedLine(R) Brain Function Monitoring and O3(TM) Regional Oximetry technologies to monitor patients in the operating room and intensive care unit.
MASI: 52.33 (+0.34)

5 Medtech Stocks to Watch Out for in 2H16
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 3:30PM CDT
The global Medtech industry is expected to grow at a CAGR of 4.1% to reach a sales value of $477.5 billion in 2020.
IART: 81.45 (+0.59), MASI: 52.33 (+0.34), LNTH: 4.65 (+0.27), LH: 135.30 (+3.33), NUVA: 60.82 (+1.11)

Luminex Closes Nanosphere Buyout, Maintains FY16 View
Zacks Equity Research - Zacks Investment Research - Mon Jul 04, 9:07AM CDT
Luminex Corp (LMNX) has finally closed the acquisition of Nanosphere Inc for $1.70 per share on Jun 30.
MASI: 52.33 (+0.34), LMNX: 21.66 (+0.46), CRY: 12.23 (+0.25), MLAB: 125.80 (+2.68)

IDEXX: International Growth Strong, Currency Woes Persist
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 6:44AM CDT
On Jul 1, we issued an updated research report on Delaware, NJ-based IDEXX Laboratories, Inc. (IDXX).
MASI: 52.33 (+0.34), IDXX: 94.96 (+1.10), CRY: 12.23 (+0.25), MLAB: 125.80 (+2.68)

Masimo's Radius 7 Wearable Monitor Gets FDA 510 (k) Nod
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 3:48PM CDT
Masimo Corporation (MASI) recently announced the receipt of FDA 510 (k) approval for the Radius 7 wearable, tetherless, non-invasive rainbow monitor device.
HYH: 34.47 (+1.10), IRMD: 22.13 (+1.20), MASI: 52.33 (+0.34), CRY: 12.23 (+0.25)

Accuray (ARAY) Receives 510(k) FDA Clearance for Radixact
Zacks Equity Research - Zacks Investment Research - Wed Jun 29, 7:41AM CDT
Accuray Inc (ARAY) recently received the much-awaited 510(k) clearance for its Radixact Treatment delivery platform.
IRMD: 22.13 (+1.20), MASI: 52.33 (+0.34), ARAY: 5.19 (+0.29), CRY: 12.23 (+0.25)

Cepheid (CPHD): New Tests Drive Growth, Competition Rife
Zacks Equity Research - Zacks Investment Research - Mon Jun 27, 7:24AM CDT
With respect to pipeline development, Cepheid's (CPHD) Xpert Trichomonas for male urine claim is currently on track for FDA submission.
IRMD: 22.13 (+1.20), MASI: 52.33 (+0.34), CPHD: 33.40 (+2.03), CRY: 12.23 (+0.25)

Luminex Well Poised on Pipeline Strength, Strategic Tie-Ups
Zacks Equity Research - Zacks Investment Research - Mon Jun 27, 7:03AM CDT
After posting a strong first quarter of 2016, Luminex (LMNX) is now expected to benefit from its ARIES System and the NxTAG Respiratory Pathogen Panel expansion plans.
IRMD: 22.13 (+1.20), MASI: 52.33 (+0.34), LMNX: 21.66 (+0.46), CRY: 12.23 (+0.25)

Quest Diagnostics Poised on Strategic Tie-Ups, New Launches
Zacks Equity Research - Zacks Investment Research - Mon Jun 27, 6:38AM CDT
On Jun 26, 2016, we issued an updated research report on Quest Diagnostics, Inc. (DGX).
HCA: 78.21 (+1.22), MASI: 52.33 (+0.34), DGX: 82.23 (+1.00), CRY: 12.23 (+0.25)

Intuitive Surgical at 52-Week High on High Procedural Volume
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 9:24AM CDT
Share price of Intuitive Surgical (ISRG) rallied to a new 52-week high of $661.94 on Jun 23, eventually closing a tad bit lower at $661.32.
ISRG: 678.84 (+3.54), IRMD: 22.13 (+1.20), MASI: 52.33 (+0.34), CRY: 12.23 (+0.25)

Accuray's (ARAY) TomoTherapy System Uptake on the Rise
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 9:00AM CDT
Accuray Inc.'s (ARAY) TomoTherapy System continues to gain traction in international markets.
IRMD: 22.13 (+1.20), MASI: 52.33 (+0.34), ARAY: 5.19 (+0.29), CRY: 12.23 (+0.25)

Intuitive Surgical: Forex & Regulatory Woes Continue to Hurt
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:06AM CDT
Intuitive Surgical has been facing several headwinds including Foreign exchange headwinds and delayed market acceptance.
ISRG: 678.84 (+3.54), IRMD: 22.13 (+1.20), MASI: 52.33 (+0.34), CRY: 12.23 (+0.25)

Zacks.com featured highlights: Cable ONE, Masimo, Globant S.A., Altisource Portfolio Solutions S.A. and CommVault Systems
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 8:30AM CDT
Zacks.com featured highlights: Cable ONE, Masimo, Globant S.A., Altisource Portfolio Solutions S.A. and CommVault Systems
CABO: 523.23 (-19.37), MASI: 52.33 (+0.34), GLOB: 40.03 (+0.75), ASPS: 26.51 (+0.92), CVLT: 44.23 (+1.20)

Stryker (SYK) Hits 52-Week High on Positive FY16 View
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 9:14AM CDT
Share price of Stryker Corp (SYK) rallied to a new 52-week high of $116.99 on Jun 20.
MASI: 52.33 (+0.34), BAX: 46.65 (+0.53), CRY: 12.23 (+0.25), SYK: 122.29 (+1.26)

These 5 Liquid Stocks Have the Potential to Outperform
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 6:48AM CDT
A strategy that seeks to invest in shares of companies having favorable liquidity positions is poised to yield healthy returns irrespective of market conditions.
CABO: 523.23 (-19.37), MASI: 52.33 (+0.34), GLOB: 40.03 (+0.75), ASPS: 26.51 (+0.92), CVLT: 44.23 (+1.20)

Thermo Fisher Grows Globally; Affimetrix Synergy on Track
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 7:17AM CDT
On Jun 20, 2016, we issued an updated research report on Thermo Fisher Scientific Inc. (TMO).
MASI: 52.33 (+0.34), TMO: 152.69 (+3.63), CRY: 12.23 (+0.25), MLAB: 125.80 (+2.68)

Global Patient Monitoring Devices Market Worth USD 33.9 Billion by 2025 - Analysis, Technologies & Forecasts Report 2016-2025 - Key Vendors: Abbott Labs, Omron Healthcare, Masimo Corp - Research and Markets
BusinessWire - Fri Jun 17, 2:40PM CDT
Research and Markets has announced the addition of the "Global Patient Monitoring Devices Market Analysis & Trends - Industry Forecast to 2025" report to their offering.
ABT: 41.89 (+0.53), MASI: 52.33 (+0.34)

IRadimed (IRMD) Raised to Strong Buy on Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:18AM CDT
On Jun 17, Zacks Investment Research raised IRadimed Corp. (IRMD) to a Zacks Rank #1 (Strong Buy).
IRMD: 22.13 (+1.20), MASI: 52.33 (+0.34), CRY: 12.23 (+0.25), MLAB: 125.80 (+2.68)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Swanson Nexus Pro Launch: Boost for Dietitians

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

CapCut's AI Tools Reshape Video Content Creation

AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...

Bio-Thera's New Data: A Game Changer for NSCLC?

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

PZZA Faces Class Action: Strategic Shake-up or Misstep?

Papa John's: Doughy Deceit or Strategic Misfire? Once in a while, a corporation trips over its own ambitious production line, and Papa John’s (NASDAQ:PZZA) is the latest contestant to make headlines for all the wrong reasons. Investors in this pizza powerhouse are being called to the courtroom as a class action lawsuit unfolds, marking a turbulent stage in the...

ASTS Faces Crucial Deadline Amidst Legal Turmoil

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

DIRECTV Bags New NHL Deals: Stakes for Sports Fans

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Beta Bionics Faces Class Action Lawsuit Amid FDA Concerns

Beta Bionics in the Legal Crosshairs When a company like Beta Bionics gets hauled into court, you know it's not just smoky mirrors and boardroom politics. The stakes are high right now, with investors lining up for a class-action lawsuit that zeroes in on a nasty bundle of allegations. This isn't just a blip on the radar. It's a seismic wave in the industry. Allegations...

Wisconsin Brats Clash with Florida Citrus in Marketing Showdown

A Juicy Rivalry with Sweet and Savory Stakes You ever catch yourself watching state pride turn into a marketing showdown? That's what's cookin' with Wisconsin's Johnsonville and Florida's Natural, and believe me, this isn't just about what’s on your plate. Forget the foam fingers, here it's all about the brats and the OJ. It's like the Packers versus the Dolphins, but...

Pathalys' Phase 3 Data Shows Promise for CKD Drug

A Glimpse at Pathalys Pharma's Recent Win This is some groundbreaking stuff emerging from Pathalys Pharma. Their investigational drug, upacicalcet, has just clinched a significant victory in two crucial Phase 3 trials - PATH-1 and PATH-2 - aimed at treating Secondary Hyperparathyroidism (SHPT) in patients with end-stage kidney disease undergoing hemodialysis. With SHPT...

DigitalXForce Booms with 514% Growth and Major Backing

Massive Growth and Strategic Investment in DigitalXForce Now here’s a company that’s shaking things up—DigitalXForce. Right on the back of a staggering 514% growth, they’ve corralled a strategic investment from Arsenal Growth Equity. If you blink, you might miss just how fast they’re sprinting through the tech landscape. Institutional Support Backing the...